The absence of reproductive toxicity data is a reflection of the speed of development to first identify and select COVID-19 mRNA Vaccine BNT162b2 for clinical testing and its rapid development to meet the ongoing urgent health need. In principle, a decision on licensing a vaccine could be taken in these circumstances without data from reproductive toxicity studies animals, but there are studies ongoing and these will be provided when available. In the context of supply under Regulation 174, it is considered that sufficient reassurance of safe use of the vaccine in pregnant women cannot be provided at the present time: however, use in women of childbearing potential could be supported provided healthcare professionals are advised to rule out known or suspected pregnancy prior to vaccination. Women who are breastfeeding should also not be vaccinated. These judgements reflect the absence of data at the present time and do not reflect a specific finding of concern. Adequate advice with regard to women of childbearing potential, pregnant women and breastfeeding women has been provided in both the Information for UK Healthcare Professionals and the Information for UK recipients.
The Authority seeks to top up the Stockpile holdings of Midazolam 50mg/10ml vial (EOL) and Noradrenaline 8mg/8ml for infs Amp (ITU) medicines in preparations for further waves of Covid 19 in Winter 2021/ Spring 2022.
The Authority seeks to procure a framework agreement for temporary body storage in the event of an excess deaths situation for the 32 London boroughs and the City of London, led by Westminster City Council. The framework agreement will appoint a single provider and will be for a period of 4 years. This will be a contingency contract, only called upon in the event that an excess deaths situation arises in the future and existing local body storage capacity needs to be augmented.
The over-arching aim of this tender is to provide a single framework supplier that will be able to provide temporary body storage facilities to house deceased in the event of an excess deaths situation. The deceased will be stored with dignity and respect, at locations to be determined based on local London needs at the time and will require some design elements to accommodate local site conditions and constraints, while being capable of rapid deployment, construction and commissioning to an agreed standard. This framework will be procured by the Authority as the pan-London lead, but all London local authorities may call-off against the framework.
This will be a contingency cover framework and as such there is no minimum guarantee of any level of spend or call-off under the framework agreement.
The Development, Concepts and Doctrine Centre (DCDC) has worked in partnership with the German Bundeswehr Office for Defence Planning to understand the future implications of human augmentation (HA), setting the foundation for more detailed Defence research and development.
The project incorporates research from German, Swedish, Finnish and UK Defence specialists to understand how emerging technologies such as genetic engineering, bioinformatics and the possibility of brain-computer interfaces could affect the future of society, security and Defence. The ethical, moral and legal challenges are complex and must be thoroughly considered, but HA could signal the coming of a new era of strategic advantage with possible implications across the force development spectrum.
HA technologies provides a broad sense of opportunities for today and in the future. There are mature technologies that could be integrated today with manageable policy considerations, such as personalised nutrition, wearables and exoskeletons. There are other technologies in the future with promises of bigger potential such as genetic engineering and brain-computer interfaces. The ethical, moral and legal implications of HA are hard to foresee but early and regular engagement with these issues lie at the heart of success.